Johnson & Johnson $JNJ Stock Position Raised by Modera Wealth Management LLC

Key Points

• Modera Wealth Management increased its Johnson & Johnson stake by 3.9% in the third quarter, bringing its holdings to 212,329 shares valued at approximately $56.2 million. Institutional investors and hedge funds collectively own 69.55% of J&J.
• Johnson & Johnson exceeded quarterly earnings expectations, reporting $2.59 in adjusted EPS and $25.40 billion in revenue, while setting fiscal 2026 EPS guidance of $11.05–$11.15. The company also declared a quarterly dividend of $1.34 per share, representing a 2.0% yield.
• Several executives sold a combined 64,515 shares worth $17.3 million over the past three months, while JNJ trades near its 52-week high with a consensus analyst rating of “Moderate Buy” and an average price target of $275.92.

Modera Wealth Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 212,329 shares of the company's stock after purchasing an additional 7,904 shares during the period. Modera Wealth Management LLC's holdings in Johnson & Johnson were worth $56,212,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. National Pension Service increased its stake in shares of Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company's stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the period. IFP Advisors Inc lifted its holdings in Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B boosted its stake in Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after purchasing an additional 2,563 shares during the period. Gradient Investments LLC boosted its stake in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock valued at $38,815,000 after purchasing an additional 13,737 shares during the period. Finally, AMG Asset Management Group Inc. grew its holdings in Johnson & Johnson by 172.0% in the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company's stock valued at $1,020,000 after buying an additional 2,436 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 64,515 shares of company stock worth $17,271,766 over the last three months. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock opened at $273.39 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $185.12 and a 12 month high of $282.02. The firm has a market cap of $658.13 billion, a P/E ratio of 41.42, a P/E/G ratio of 2.70 and a beta of 0.22. The company's 50-day moving average price is $265.74 and its two-hundred day moving average price is $246.94.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the firm posted $2.80 EPS. The firm's quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Wall Street Analyst Weigh In

Several research analysts have weighed in on JNJ shares. Argus set a $300.00 price objective on Johnson & Johnson in a research report on Wednesday, July 29th. Weiss Ratings cut shares of Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research report on Friday, October 23rd. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 14th. HSBC raised their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.